Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/recent-advances-in-antiretroviral-treatment-and-prevention-in-hiv-Yc31FfmSb0
References (71)
-
M. Girard, S. Osmanov, M. Kieny (2006)
A review of vaccine research and development: the human immunodeficiency virus (HIV).Vaccine, 24 19
-
(2009)
Investígator's brochure update (SCH417690): summary oÍ important changes 04 Aug -
C. Cohen, J. Molina, P. Cahn, B. Clotet, J. Fourie, B. Grinsztejn, W. Hao, M. Johnson, K. Supparatpinyo, H. Crauwels, L. Rimsky, S. Vanveggel, P. Williams, K. Boven (2010)
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patientsJournal of the International AIDS Society, 13
-
D. Havlir, I. Marschner, M. Hirsch, A. Collier, P. Tebas, Roland Bassett, J. Ioannidis, M. Holohan, R. Leavitt, G. Boone, D. Richman (1998)
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.The New England journal of medicine, 339 18
-
J. Suleiman, B. Zingman, R. Diaz, J. Madruga, E. Dejesus, J. Slim, Carmen Mak, Erin Lee, M. McCarthy, L. Dunkle, S. Walmsley (2010)
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.The Journal of infectious diseases, 201 4
-
P. Kwong, R. Wyatt, James Robinson, R. Sweet, J. Sodroski, W. Hendrickson (1998)
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyNature, 393
-
M. Cohen, C. Gay (2010)
Treatment to prevent transmission of HIV-1.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 3
-
S30 Recent advances in antirêtroviÍal treatment and prevention in H|V-inÍected patients 79 -
R. Gulick, Zhaohui Su, C. Flexner, M. Hughes, P. Skolnik, T. Wilkin, R. Gross, A. Krambrink, E. Coakley, W. Greaves, A. Zolopa, R. Reichman, C. Godfrey, M. Hirsch, D. Kuritzkes (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.The Journal of infectious diseases, 196 2
-
P. Pitisuttithum (2008)
HIV vaccine research in Thailand: lessons learnedExpert Review of Vaccines, 7
-
F. Goebel, A. Yakovlev, A. Pozniak, E. Vinogradova, G. Boogaerts, R. Hoetelmans, M. Béthune, M. Peeters, B. Woodfall (2006)
Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjectsAIDS, 20
-
The present paper provides prelimìnary evidence Íor the effectiveness of a vaccine in preventing HIV-l infection in a community-based population -
H. Khanlou, V. Yeh, Bill Guyer, C. Farthing (2005)
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.AIDS patient care and STDs, 19 3
-
S. Swindells, A. DiRienzo, T. Wilkin, C. Fletcher, D. Margolis, G. Thal, C. Godfrey, B. Bastow, M. Ray, Hongying Wang, R. Coombs, J. McKinnon, J. Mellors (2006)
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.JAMA, 296 7
-
(2002)
Phambili) Why we unblinded Phambilì. HWN fuìl group meeting, Seattle -
(2008)
A phase 2 safety and eÍficacy study of bevirimat (BVM) in heavily treaÌment experienced HIV+ patients idenlifies the target phase 3 study profile [abstract no -
M. Opravil, B. Hirschel, A. Lazzarin, H. Furrer, J. Chave, S. Yerly, L. Bisset, M. Fischer, P. Vernazza, E. Bernasconi, M. Battegay, B. Ledergerber, H. Günthard, C. Howe, R. Weber, L. Perrin (2002)
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.The Journal of infectious diseases, 185 9
-
A. Zolopa, D. Berger, H. Lampiris, Lijie Zhong, S. Chuck, J. Enejosa, B. Kearney, A. Cheng (2010)
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.The Journal of infectious diseases, 201 6
-
J. Ananworanich, A. Gayet-Ageron, Michelle Braz, W. Prasithsirikul, P. Chetchotisakd, S. Kiertiburanakul, Warangkana Munsakul, P. Raksakulkarn, Somboon Tansuphasawasdikul, S. Sirivichayakul, M. Cavassini, Urs Karrer, D. Genné, R. Nüesch, P. Vernazza, E. Bernasconi, Dominic Leduc, C. Satchell, S. Yerly, L. Perrin, A. Hill, T. Perneger, P. Phanuphak, H. Furrer, David Cooper, K. Ruxrungtham, B. Hirschel (2006)
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialThe Lancet, 368
-
G. Pialoux, F. Raffi, F. Brun-vezinet, V. Meiffrédy, P. Flandre, J. Gastaut, P. Dellamonica, P. Yeni, J. Delfraissy, J. Aboulker (1998)
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.The New England journal of medicine, 339 18
-
J. Hurwitz, X. Zhan, Scott Brown, M. Bonsignori, J. Stambas, T. Lockey, R. Sealy, S. Surman, P. Freiden, B. Jones, L. Martin, J. Blanchard, K. Slobod (2008)
HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.Frontiers in bioscience : a journal and virtual library, 13
-
(2008)
Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted riÍabutin labstract no. P1g]. 9th International Workshop on -
Kimberly Schoenly, D. Weiner (2007)
Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform “Spotty Business”Journal of Virology, 82
-
M. Girard, G. Bansal (2008)
HIV/AIDS Vaccines: A Need for New Concepts?International Reviews of Immunology, 27
-
C. Stoddart, P. Joshi, B. Sloan, J. Bare, Philip Smith, G. Allaway, C. Wild, David Martin (2007)
Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv MicePLoS ONE, 2
-
K. Lo (2008)
The first postmodern pandemic: 25 years of HIV/ AIDS.Journal of Internal Medicine, 263
-
Olof Karlström, F. Josephson, A. Sönnerborg (2007)
Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance MonotherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 44
-
(2007)
Lack of clinically relevant drugdrug inÌeraction between ritonavirboosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract]. 4th International AIDS Society Conference -
J. Mallolas, J. Pich, M. Peñaranda, P. Domingo, H. Knobel, E. Pedrol, F. Gutiérrez, P. Barrufet, J. Peraire, M. Asenjo, F. Vidal, J. Gatell (2008)
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adultsAIDS, 22
-
María Pérez-Elías, A. Moreno, S. Moreno, Dolores López, A. Antela, José Casado, F. Dronda, C. Gutiérrez, C. Quereda, E. Navas, V. Abraira, Miguel Rodríguez (2005)
Higher Virological Effectiveness of NNRTI-Based Antiretroviral Regimens Containing Nevirapine or Efavirenz Compared to a Triple NRTI Regimen As Initial Therapy in HIV-1-Infected AdultsHIV Clinical Trials, 6
-
C. Katlama, M. Valantin, M. Algarte-Genin, C. Duvivier, S. Lambert-Niclot, P. Girard, J. Molina, B. Hoen, Sophie Pakianather, G. Peytavin, A. Marcelin, P. Flandre (2010)
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 24
-
W. Bierman, M. Agtmael, M. Nijhuis, S. Danner, C. Boucher (2009)
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS, 23
-
J. McKinnon, J. Mellors, S. Swindells (2009)
Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and ProspectsAntiviral Therapy, 14
-
R. Puls, S. Emery (2006)
Therapeutic vaccination against HIV: current progress and future possibilities.Clinical science, 110 1
-
T. Wilkin, J. McKinnon, A. DiRienzo, K. Mollan, Courtney Fletcher, D. Margolis, B. Bastow, G. Thal, W. Woodward, C. Godfrey, A. Wiegand, F. Maldarelli, S. Palmer, John Coffin, J. Mellors, S. Swindells (2009)
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.The Journal of infectious diseases, 199 6
-
(2008)
EÍIicacy , saÍety and tolerabil ity of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients labstract no . MOPEB 067 ] -
M. Markowitz, Christina Hill‐Zabala, Joseph Lang, E. Dejesus, Qiming Liao, E. Lanier, E. Davis, M. Shaefer (2005)
Induction With Abacavir/Lamivudine/Zidovudine Plus Efavirenz for 48 Weeks Followed by 48-Week Maintenance With Abacavir/Lamivudine/Zidovudine Alone in Antiretroviral-Naive HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 39
-
(2007)
Clin Pharmacol Ther -
S. Buchbinder, D. Mehrotra, A. Duerr, D. Fitzgerald, R. Mogg, David Li, P. Gilbert, J. Lama, M. Marmor, C. Rio, M. McElrath, D. Casimiro, K. Gottesdiener, J. Chodakewitz, L. Corey, Michael Robertson (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 372
-
R. Gagliano (2006)
Review ofUbiquity, 2006
-
Olof Karlström, F. Josephson, A. Sönnerborg (2007)
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.Journal of acquired immune deficiency syndromes, 44 4
-
D. Schürmann, G. Fätkenheuer, J. Reynes, C. Michelet, F. Raffi, J. Lier, M. Caceres, A. Keung, Angela Sansone-Parsons, L. Dunkle, C. Hoffmann (2007)
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adultsAIDS, 21
-
S. Sahali, M. Chaix, J. Delfraissy, J. Ghosn (2008)
Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.AIDS reviews, 10 1
-
S. Ramanathan, S. Abel, S. Tweedy, S. West, J. Hui, B. Kearney (2010)
Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and MaravirocJAIDS Journal of Acquired Immune Deficiency Syndromes, 53
-
U. Wille-Reece, B. Flynn, K. Loré, R. Koup, A. Miles, A. Saul, R. Kedl, J. Mattapallil, W. Weiss, M. Roederer, R. Seder (2006)
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primatesThe Journal of Experimental Medicine, 203
-
B. Dau, M. Holodniy (2009)
Novel Targets for Antiretroviral TherapyDrugs, 69
-
C. Danel, R. Moh, A. Minga, A. Anzian, O. Ba-Gomis, C. Kanga, G. Nzunetu, D. Gabillard, F. Rouet, Souleymane Sorho, M. Chaix, S. Eholie, H. Menan, D. Sauvageot, E. Bissagnéné, R. Salamon, X. Anglaret (2006)
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trialThe Lancet, 367
-
R. Landovitz, J. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, G. Fätkenheuer (2008)
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.The Journal of infectious diseases, 198 8
-
Jason Schafer, K. Squires (2010)
Integrase Inhibitors: A Novel Class of Antiretroviral AgentsAnnals of Pharmacotherapy, 44
-
A. Boberg, M. Isaguliants (2008)
Vaccination against drug resistance in HIV infectionExpert Review of Vaccines, 7
-
R. Gulick, H. Ribaudo, C. Shikuma, S. Lustgarten, K. Squires, W. Meyer, E. Acosta, B. Schackman, C. Pilcher, R. Murphy, W. Maher, M. Witt, R. Reichman, S. Snyder, K. Klingman, D. Kuritzkes (2004)
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.The New England journal of medicine, 350 18
-
R. Koup, J. Safrit, Yun-zhen Cao, C. Andrews, G. McLeod, W. Borkowsky, C. Farthing, D. Ho (1994)
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndromeJournal of Virology, 68
-
M. Thompson, J. Aberg, H. Günthard (2010)
Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel -
A. Pozniak, J. Morales-Ramirez, E. Katabira, D. Steyn, S. Lupo, Mario Santoscoy, B. Grinsztejn, K. Ruxrungtham, L. Rimsky, S. Vanveggel, K. Boven (2010)
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialAIDS, 24
-
R. Detels, A. Muñoz, G. McFarlane, L. Kingsley, J. Margolick, J. Giorgi, L. Schrager, J. Phair (1998)
Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.JAMA, 280 17
-
D. Barouch (2008)
Challenges in the development of an HIV-1 vaccineNature, 455
-
W. El-Sadr, W. El-Sadr, J. Lundgren, J. Neaton, F. Gordin, D. Abrams, R. Arduino, A. Babiker, W. Burman, N. Clumeck, C. Cohen, D. Cohn, D. Cooper, J. Darbyshire, S. Emery, G. Fätkenheuer, B. Gazzard, B. Grund, J. Hoy, K. Klingman, M. Losso, N. Markowitz, J. Neuhaus, A. Phillips, C. Rappoport (2006)
CD4+ count-guided interruption of antiretroviral treatment.The New England journal of medicine, 355 22
-
Xiping Wei, J. Decker, Shuyi Wang, H. Hui, J. Kappes, Xiaoyun Wu, J. Salazar-Gonzalez, M. Salazar, J. Kilby, M. Saag, N. Komarova, M. Nowak, B. Hahn, P. Kwong, G. Shaw (2003)
Antibody neutralization and escape by HIV-1Nature, 422
-
S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, Nakorn Premsri, C. Namwat, M. Souza, Elizabeth Adams, M. Benenson, S. Gurunathan, Jim Tartaglia, J. McNeil, Donald Francis, D. Stablein, D. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. Robb, Nelson Michael, P. Kunasol, Jerome Kim (2009)
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.The New England journal of medicine, 361 23
-
H. Robinson (2007)
HIV/AIDS Vaccines: 2007Clinical Pharmacology & Therapeutics, 82
-
Y. Mehellou, E. Clercq (2010)
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?Journal of medicinal chemistry, 53 2
-
(2009)
Efficacy, safety and pharmacokinetics of MPC-4326 (bevirimat dimeglumine) 200m9 BID and 300m9 BID monotherapy adminìstered for'14 days in subjects with HIV-1 inÍecÌion lslide presentationl -
J. Gallant, Allan Rodriguez, W. Weinberg, B. Young, D. Berger, Michael Lim, Qiming Liao, L. Ross, Judy Johnson, M. Shaefer (2005)
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.The Journal of infectious diseases, 192 11
-
P. Borrow, H. Lewicki, B. Hahn, G. Shaw, M. Oldstone (1994)
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infectionJournal of Virology, 68
-
Patrick Smith, A. Ogundele, A. Forrest, J. Wilton, K. Salzwedel, Judy Doto, G. Allaway, David Martin (2007)
Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 51
-
C. Katlama, S. Fenske, B. Gazzard, A. Lazzarin, N. Clumeck, J. Mallolas, A. Lafeuillade, J. Mamet, Lauriane Beauvais (2003)
TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence resultsHIV Medicine, 4
-
L. Baert, G. Klooster, W. Dries, M. François, A. Wouters, E. Basstanie, K. Iterbeke, F. Stappers, P. Stevens, Laurent Schueller, P. Remoortere, Guenter Kraus, P. Wigerinck, J. Rosier (2009)
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 72 3
-
K. Koelsch, D. Cooper (2009)
Integrase inhibitors in salvage therapy regimens for HIV-1 infectionCurrent Opinion in HIV and AIDS, 4
-
J. Delfraissy, P. Flandre, C. Delaugerre, J. Ghosn, A. Horban, P. Girard, M. Norton, C. Rouzioux, A. Taburet, I. Cohen-Codar, P. Van, J. Chauvin (2008)
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsAIDS, 22
-
Kevin Brown, Sunita Paul, A. Kashuba (2009)
Drug Interactions with New and Investigational AntiretroviralsClinical Pharmacokinetics, 48
-
B. Gazzard (2005)
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008HIV Medicine, 9
- Publisher
- Wolters Kluwer Health
- ISSN
- 1746-630X
- eISSN
- 1746-6318
- DOI
- 10.1097/01.COH.0000410238.80894.81
- Publisher site
- See Article on Publisher Site
Abstract
Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/12/2020 Recent advances in antiretroviral treatment and prevention in HIV-infected patients a b c d Fernando Malteˆz , Manuela Doroana , Teresa Branco and Cristina Valente Infectious Diseases Service – H. Curry Cabral, Purpose of review Infectious Diseases Service – H. Santa Maria, Centro To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies Hospitalar Lisboa Norte, Medical Service – H. Fernando da Fonseca, Lisbon and Infectious that are currently being evaluated, and to provide an overview of the most recent Diseases Service – Centro Hospitalar de Coimbra, advances in HIV vaccine development. Coimbra, Portugal Recent findings Correspondence to Fernando Malte ˆ z, Infectious There is a continuous need for improvements in ARV therapy (ART) and several new Diseases Service, Hospital de Curry Cabral, Rua da Beneficie ˆ ncia n8 8, 106-166 Lisboa, Portugal ARVs are currently undergoing clinical investigation, including the non-nucleoside Tel: +00351 217924280; fax: +00351 217924281; reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the e-mail: fmaltez@hccabral.min-saude.pt chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor Current Opinion in HIV and AIDS 2011, bevirimat. Strategies to optimize ART, such as treatment interruption, induction- 6 (suppl 1):S21 – S30
Journal
Current Opinion in HIV & AIDS – Wolters Kluwer Health
Published: Dec 1, 2011